

RECORDATI: DOCUMENTS RELATING TO THE ORDINARY GENERAL MEETING OF THE SHAREHOLDERS 21.04.2023

Milan, 30th March 2023 – Please be informed that the **2022 Annual Financial Report** (including the Separate Financial Statements and the Consolidated Financial Statements as at 31st December 2022 with the related Directors' Management Report and the required Statements) and the **2022 Consolidated Non-Financial Statement**, both accompanied by the **Reports issued by the Auditing Firm**, as well as the **Report issued by the Board of Statutory Auditors**, are available to the public, as of today, at the Company's registered office and published on the Company's website (www.recordati.it - Investors – Shareholders' Meeting section) and on the '1INFO' storage mechanism (www.1info.it).

In addition, please be informed that the following reports approved by the Board of Directors of Recordati S.p.A. on 16th March 2023:

- (i) the **2022 Corporate Governance Report and Ownership Structure**; and
- (ii) the **Directors' Report relating to item no. 1 (Financial statements approval and allocation of profit)** of the agenda of the Ordinary Shareholders' Meeting called for 21st April 2023,

are also available to the public, as of today, at the Company's registered office and published on the Company's website (www.recordati.it, the first report in the Corporate Governance – Report on Corporate Governance and the Ownership Structure section; and the second report in the Investors - Shareholders' Meeting section) and on the '1INFO' storage mechanism (www.1info.it).

Recordati (Reuters RECI.MI, Bloomberg REC IM), established in 1926, is an international pharmaceutical group listed on the Italian Stock Exchange (ISIN IT 0003828271), with a total staff of more than 4,300, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Headquartered in Milan, Italy, Recordati has operations in Europe, Russia and other countries of the CIS, Ukraine, Turkey, North Africa, the United States, Canada, Mexico, some South American countries, Japan, Australia and New Zealand, China and South Korea. An efficient field force of medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under licence, from a number of therapeutic areas, including a global specialised business, dedicated to rare diseases. Recordati is a partner of choice for new product licences for its territories. Recordati is committed to the research and development of new specialties with a focus on treatments for rare diseases. Consolidated revenue for 2022 was € 1,853.3 million, operating income was € 437.3 million and net income was € 312.3 million.

For further information:

Recordati website: www.recordati.it

Investor Relations

Federica De Medici

(39) 02 48787146

e-mail: investorelations@recordati.it

Investor Relations

Lucia Abbatantuoni

(39) 02 48787213

e-mail: investorelations@recordati.it

Media Relations

Brunswick: Barbara Scalchi / Andrea Mormandi

(39) 02 9288 6200

e-mail: recordati@brunswickgroup.com

RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.A.

Registered Office

Via Matteo Civitali, 1

20148 Milano, Italy

Ph. (39) 02 487871

Fax (39) 02 40073747

www.recordati.com

Share Capital € 26.140.644,50 fully paid-up

Milano, Monza, Brianza and Lodi Comp. Reg. No. 00748210150

Tax Code/VAT No. 00748210150

Milano R.E.A. No. 401832

Company subject to the Management and Coordination Activity of Rossini Luxembourg S.à.r.l